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Background: The incidence of sick sinus syndrome will increase due to population ageing. Consequently, this will
result in an increase in the number of pacemaker implantations. The atrial lead is usually implanted in the right
atrial appendage, but this position may be ineffective for prevention of atrial fibrillation. It has been suggested that
pacing distally in the coronary sinus might be more successful in preventing atrial fibrillation episodes. The aim of
this trial is to study the efficacy of distal coronary sinus versus right atrial appendage pacing in preventing atrial
fibrillation episodes in patients with sick sinus syndrome.
Methods/Design: This study is designed as a multicenter, randomized controlled trial. Patients with sick sinus
syndrome and at least one atrial fibrillation episode of 30 seconds or more in the six months before recruitment
will be eligible for participation in this study.
All participants will be randomized between pacing distally in the coronary sinus and right atrial appendage.
Randomization is stratified for all participating centers. Conventional dual-chamber pacemakers with advanced
home monitoring functionality will be implanted. The ventricular lead will be implanted in the right ventricular
apex. The first three months of the 36-month follow-up period are considered as run-in time. During the
pre-randomization visit and follow-up, an interview, electrocardiogram and pacemaker assessment will be
performed, prescribed antiarrhythmic medication will be reviewed and patients will be asked to complete an SF-36
questionnaire. An echocardiographic examination will be conducted in the pre-randomization phase and at the end
of each follow-up year. Home monitoring will be used to send daily reports in case of atrial fibrillation episodes.
Discussion: This randomized controlled trial is the first in which home monitoring will be used to compare atrial
fibrillation recurrences between pacing in the distal coronary sinus or right atrial appendage. Home monitoring gives
the opportunity to accurately detect atrial fibrillation episodes and to study characteristics of atrial fibrillation episodes.
Should distal coronary sinus pacing significantly diminish atrial fibrillation recurrences, this study will redefine the
preferential location of an atrial lead for preventive pacing.
Trial registration: Current Controlled Trials ISRCTN65911661, registered on 8 July 2013.
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Sinus node disease is defined as an intrinsic, symptom-
atic form of sinus node dysfunction and was first de-
scribed by Wenckebach in 1923. It is also known as the
sick sinus syndrome (SSS) and develops at a mean age of
68 years [1-5].
It is expected that the incidence of SSS will continue
to increase due to ageing of the population, as impulse
formation within the sinus node declines over time [6].
This may be caused by destruction of the sinus node it-
self or ischemia, inflammation or degeneration of the
surrounding nerves or ganglia. If more than 90% of the
sinus node tissue is damaged, SSS develops. However,
sinus node dysfunction may also have extrinsic causes
including antiarrhythmic drug usage, electrolyte distur-
bances, hypothermia, hypothyroidism, increased intra-
cranial pressure and excessive vagal tone [6]. Sinus node
disease accounts at present for approximately 35 to 45%
of the pacemaker implantations in Europe and the
United States and it is expected that the number of sub-
jects requiring cardiac pacing will continue to rise in the
coming decades [1,6-9]. Within this group, 30% have
symptomatic paroxysmal atrial fibrillation (PAF) [10].
The combination of sinus bradycardia or sinoatrial block
and paroxysms of atrial fibrillation (AF) is also known as
the brady-tachy syndrome [1,4]. AF is associated with se-
vere implications including heart failure and stroke; 20%
of all strokes can be attributed to AF and patients with
AF have a five-fold higher risk of stroke [11].
A meta-analysis by Coplen et al. revealed that only 50%
of the PAF patients who were treated with anti-arrhythmic
drugs remained in sinus rhythm (SR) during a one-year
follow-up period [12]. In addition, the heart rate of SSS
patients, who already have a sinus bradycardia, will be-
come even lower when using antiarrhythmic drugs for
symptomatic episodes of AF. In the PAF study, atrioven-
tricular junctional (AVJ) ablation with DDD pacemaker
implantation was compared with pharmacological treat-
ment [13]. Quality of life scores were higher in the non-
pharmacological group and these patients were also less
symptomatic.
However, AVJ junctional ablation is often considered
the final step of AF therapy due to its irreversible nature.
Chen et al. proposed that catheter ablation of AF can
improve sinus node dysfunction, since 95% of the pa-
tients did not have a pacemaker indication after the pro-
cedure [14]. However, these patients were relatively
young and not all patients with severe symptomatic SSS
may benefit from this approach. Therefore, preventive
pacing could be an appropriate treatment modality for
this group of patients.
The aim of the ‘Right versus Left Atrial Pacing in
Patients with Sick Sinus Syndrome and Paroxysmal
Atrial Fibrillation’ (Riverleft) trial is to study the efficacyof distal coronary sinus (dCS) versus right atrial append-
age (RAA) pacing in preventing AF recurrences in patients
with SSS and PAF. Characteristics of AF episodes, such as
the number and duration of recurrent AF episodes, will be
examined and compared between both study arms. The
selected pacemaker (Evia DR-T or Eluna DR-T, Biotronik,
SE & Co. KG) for the Riverleft study is equipped with
home monitoring (HM) technology, which makes con-
tinuous assessment of cardiac rhythm feasible [15,16].
Methods/Design
Study design
Riverleft is a multicenter, randomized controlled trial with
an inclusion period of approximately two years and a
follow-up period of three years for each enrolled patient.
An overview of the Riverleft study design is given in
Figure 1.
All participating centers will have an appointed local in-
vestigator who will be responsible for appropriate inclu-
sion, implantation and follow-up. Furthermore, all centers
will have an independent cardiologist, who patients with
questions regarding the Riverleft trial can contact.
Study population
Patients of 18 years or older, with either intrinsic or extrin-
sic (antiarrhythmic drug-induced) SSS and at least one
PAF episode of 30 seconds or more within six months be-
fore enrollment, will be eligible to participate in the study.
PAF episodes will be assessed by 24-hour Holter record-
ing, preceding enrollment.
All patients with a clinically estimated life expectancy of
five years or less or mental and/or physical inability to
accomplish the follow-up period, will be excluded from
participation in the Riverleft study. Left ventricular ejec-
tion fraction of 40% or less, malignancies and congenital
heart defects are also exclusion criteria. Furthermore,
chronic obstructive pulmonary disease classified as GOLD
4 and renal disease resulting in a glomerular filtration rate
of ≤30 mL/min or creatinine value of ≥250 umol/L will
prevent candidates from participation. The local investiga-
tor will only enroll eligible subjects after a signed informed
consent form (ICF) is obtained.
Sample size
A total number of 300 patients is required to detect a
difference with a power of 0.8 between both study arms
in recurrences of PAF. To maintain statistical power in
case of dropout rates as high as 10%, 330 participants
will be enrolled.
Primary outcomes
The main objective of this study is to determine the ef-
fect of dCS pacing compared to RAA pacing for the pre-
vention of recurrent AF episodes. Total number of AF
Figure 1 Overview of the Riverleft study design. Eligible patients will be informed about the study and asked to participate. Signed informed
consent will be obtained prior to enrollment. In the next phase, the participant will be randomized between right atrial appendage (RAA) pacing
and distal coronary sinus (dCS) pacing. A three-month run-in time will start after implantation. Adjustments to pacemaker settings and prescribed
medication can be made without any consequences for the study. After finishing the run-in period, adjustments to pacemaker (PM) settings or
prescribed drugs are only allowed if necessary. Electrocardiogram (ECG) will be made at each visit, an echocardiogram et the end of each follow-up
year. The study will end for each participant after a 36-month follow-up period.
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and compared between both groups.
Secondary outcomes
The relationship between pacing site, reduction of AF
episodes, quality of life, heart failure, cerebrovascular ac-
cident (CVA), number of cardioversions, frequency and
duration of hospital admission and AF progression to
persistent AF will be examined.
Randomization
Enrolled patients will be added to a tailor-made website,
which will automatically randomize participants to either
the control group (RAA pacing) or experimental group
(dCS pacing). Randomization is stratified for all partici-
pating medical centers.
Study groups
The study consists of two study arms; an atrial lead will
be positioned in RAA position (group I) or in the dCS
(group 2). Crossover will not be feasible due to the de-
sign of the study. All participants in both groups willhave a ventricular lead implanted in the right ventricular
apex (RVA). A conventional dual chamber with HM func-
tionalities will be implanted in all patients.
Study phases
Pre-randomization
Patients who meet the inclusion criteria will be approached
by the local investigator or nurse practitioner to explain
the Riverleft study and to hand over a patient information
form. Candidates will be asked to participate in this study
after a one-week reflection period. The nurse practitioner
will call back or visit the candidate if the patient is hospi-
talized, and will obtain a signed ICF. Due to the obligation
to give the patient a reflection period of seven days, pace-
maker implantations in an acute setting cannot be enrolled
in this study.
Eligible candidates, who agreed to participate in the
study, will be scheduled for a visit to a cardiologist. Dur-
ing the intake visit, the patient will be asked to complete
a health survey questionnaire (SF-36). Further examin-
ation includes an electrocardiogram (ECG) and cardiac
echocardiography. Left atrial size will be determined in
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In addition, left ventricular end systolic and left ven-
tricular end diastolic diameter will be measured and dia-
stolic function will be assessed by computing the ratio of
early to late diastolic filling, the E/A ratio.
Medical records will be reviewed to determine the mo-
ment of SSS and PAF onset, to document accompanying
symptoms during an AF episode and to assess risk fac-
tors, prescribed antiarrhythmic drugs and major events
which are defined as CVA’s, transient ischemic attacks
(TIA) or myocardial infarction. Practical and techno-
logical aspects of the selected pacemaker and HM will
be explained by the pacemaker technician.
Implantation
The atrial lead will be placed in either the RAA (Solia,
Biotronik, SE & Co. KG, Berlin, Germany) or dCS (Select-
Secure 3830, Medtronic, Inc or Optisense Optim, St. Jude
Medical, Inc or Solia, Biotronik, SE & Co. KG, Berlin,
Germany). A SelectSecure 3830 will be positioned in the
CS by using a steerable sheath (Steerable attain, C304-
L6905, Medtronic Inc., Minneapolis, Minnesota, USA).
Optimal lead position is determined by continuous moni-
toring of sensing and threshold and far field R wave
(FFRW) values during slow retraction of the sheath. The
tip of the steerable sheet will be bent and the lead will be
screwed into the wall of the CS. Next, the steerable sheath
will be removed completely. Implantation of an Optisense
Optim lead (St. Jude Medical, St, Paul, Minnesota, USA),
with a short tip-to-ring distance, will be considered in the
event of unsatisfactory high levels of FFRW sensing. The
investigators haven chosen screw-in leads in order to pre-
vent CS lead displacements and to prevent high levels of
atrial thresholds in the CS position as much as possible. A
Solia screw-in lead in the CS position will be considered in
the event of limited availability of a SelectSecure 3830 or
Optisense Optim in the participating centre. A ventricular
lead (Solia, Biotronik, SE & Co. KG, Berlin, Germany) is
implanted in the RVA position. If this is not possible, the
right ventricular outflow tract (RVOT) will be chosen as
the alternative pacing site. Lead positioning is confirmed
by using fluoroscopy. The implanting specialist will be ad-
vised to implant in the RVA or RVOT, in case of possible
disparity in implanted numbers of RVA or RVOT between
both study arms.
Conventional dual chamber pacemakers (Evia DR-T or
Eluna DR-T pacemaker, Biotronik, SE & Co. KG, Berlin,
Germany) with HM functionalities will be implanted.
The basic rate will be adjusted to 70 beats per minute.
Sensor rate and atrioventricular settings will be adjusted
according to optimal levels for each individual patient.
The closed loop stimulation (CLS) algorithm will be
switched on, unless indicated otherwise. Pacemaker set-
tings are encrypted and stored on a USB flash drive (16gigabyte SanDisk Cruzer Glide USB Flash Drive, SanDisk
corporation, Milpitas, California, USA) and imported to
a dedicated website.
Hospital discharge
The pacemaker technician will give instructions regarding
HM and will hand over a CardioMessenger II-S (Biotronik,
SE & Co. KG, Berlin, Germany). The CardioMessenger re-
quires only one wall socket and presence of a global sys-
tem for mobile communications network for the first line
of communication. This device will be installed in the bed-
room of the participant.
Wound inspection
Patients will visit the outpatient clinic one week after
pacemaker implantation. The pacemaker pocket will be
inspected and in addition, correct functioning of the
pacemaker and HM will be evaluated.
Run-in time
A three-month run-in time is reserved to allow lead
stabilization, optimize pacemaker settings and establish
an effective drug regimen. AF episodes registered in the
three-month run-in time will not be added to the total
number of counted AF episodes. Local investigators are
requested to keep pacemaker settings and drug regimen
unchanged during the rest of the follow-up period. Un-
avoidable modifications may be performed but have to
be reported.
Follow-up
The three year follow-up period will consist of eight out-
patient clinical visits. During an outpatient clinical visit,
the cardiologist or nurse practitioner will interview the pa-
tient and a SF-36 questionnaire will be completed. Drug
regimen will be reviewed for changes outside the run-in
time. Comparable to the pre-randomization phase, an
ECG will be made. Echocardiographic examination will be
conducted every year in order to perform the same mea-
surements as described in the pre-randomization phase.
The pacemaker technician will assess pacemaker perform-
ance, store reports in the pacemaker memory and, if neces-
sary, modifications in the pacemaker settings on encrypted
USB flash drive.
Alongside clinical visits, HM will give the investigators
the opportunity to receive a report from the implanted
pacemaker on a daily basis. The CardioMessenger will
automatically receive data from the implanted pace-
maker once a day and will send this dataset to the HM
website (Biotronik, SE& Co. KG). This report will con-
tain measured values of sensing, threshold, impedance
and program settings including CLS.
In addition, HM will report on registered episodes of
high atrial rate, number of mode switches and ongoing
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tion with the Riverleft website are explained in Figure 2.
An Evia DR-T or Eluna DR-T pacemaker (Biotronik, SE &
Co. KG) synchronizes with a CardioMessenger, preferably
placed on the night table. The CardioMessenger will
transmit the acquired data to the HM datacenter. Next,
the tailor-made website will receive an email with the ac-
quired data.
Adverse events
According to the regulations of the medical ethics commit-
tee (MEC), it is compulsory to register all (serious) adverse
events. Lead dislocation, pacemaker pocket infection, CVA,
TIA and death are considered as (serious) adverse events.
Dedicated website
We intended a nearly paperless study in order to make the
study less vulnerable to errors. For this purpose, a tailor-
made website was developed for the Riverleft study. Each
participating medical center will have access to a dedicated
part of the website. After enrollment and randomization
of the participant on the website, obtained data from
reviewed medical records and drug regimen, performed
interview and ECG, conducted echocardiogram and SF-36
questionnaire will be completed on the website. The web-
site will be completed after each outpatient clinical visit
during the follow-up period. The follow-up status of all
patients can be viewed instantly.Figure 2 The three modules of home monitoring and the connection
Co. KG) synchronizes with a CardioMessenger, preferably placed on the nig
2 meters are mandatory for correct synchronizing between pacemaker and
home monitoring (HM) center. Finally, an email, with the report attached, wThis website will also receive emails from the HM
monitoring website in case of recurrences of AF. Reports
on episodes of high atrial rate and number of mode
switches will be imported and stored on the website. If
necessary, pharmacological therapy will be modified or
cardioversions will be scheduled. All adverse events will
also be documented on the tailor-made website.Safety monitoring
Two committees and one monitor were appointed for
patient safety purposes. A data safety monitoring board
will review the study progress, make recommendations
regarding established protocol and study progress and
has the ability to stop the study due to significant bene-
fits or adverse effects in one of the two study arms. This
board has three members: an experienced cardiologist,
statistician and a researcher. The clinical events commit-
tee will study all (serious) adverse events for a causal re-
lationship between event and the Riverleft study. An
independent cardiologist will evaluate protocol compli-
ance and study progress by taking random samples in all
participating centers.Ethics
The study protocol was approved in October 2012 by
the MEC (2012-087) in the Erasmus Medical Center,
Rotterdam, The Netherlands.with the Riverleft website. An Evia DR-T pacemaker (Biotronik, SE &
ht table. The minimal distance of 20 cm and the maximum distance of
CardioMessenger. The CardioMessenger will send a report to the
ill be sent from the HM website to the Riverleft website.
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This study is designed to compare recurrences of AF ep-
isodes between two treatment groups. Therefore the
Fisher’s exact test will be used for this categorical data to
assess the difference in AF recurrence. Continuous data
regarding duration and total number of AF recurrences
will be analyzed by the Student’s t-test. Kaplan-Meier
curves will be constructed to compare event-free sur-
vival between both groups. Secondary outcomes will be
analyzed by a multivariate analysis. A P value of 0.05 is
considered to be statistically significant.
Discussion
This randomized controlled trial is the first of its kind in
which HM will be used to compare AF episodes, total
number and duration of AF recurrences between RAA
pacing and dCS pacing.
Mechanism of atrial fibrillation in patients with sick sinus
syndrome
Local conduction abnormalities may be involved in the
pathogenesis of AF. Atrial conduction delay was found in
68% of patients undergoing pacemaker implantation for
sinus node disease [17]. In order to study heterogeneity in
conduction in SSS patients (with or without AF) electro-
physiological studies were conducted during SR to deter-
mine the degree of fractionation in the right atrium (RA)
[18-23]. Fractionation indicates asynchronous activation
of atrial tissue and extensive fractionation may predispose
to the development of PAF. Fractionated electrograms
were recorded in more than 80% of SSS patients with
PAF. Compared to SSS patients without AF, fractionation
was more extensive in patients with AF [18,19]. The
spatial distribution of fractionated atrial electrograms in
the RA was assessed in a subsequent study. In SSS pa-
tients with paroxysms of AF, fractionated electrograms
were recorded diffusely from the higher, middle and lower
part of the RA. In contrast, fractionated electrograms in
SSS patients without PAF were predominantly recorded in
the high RA. Hence, these findings suggest that episodes
of AF in SSS patients are associated with widespread
electrophysiological alterations in the RA [20]. Next, the
relationship between fractionated electrograms and induc-
ibility of AF was studied in SSS patients; inducibility of AF
was related to the incidence and severity of fractionation
[21,22]. In addition, fractionated electrograms were more
frequently recorded in older SSS patients with PAF. These
findings may explain why older SSS patients are more
prone to developing PAF [23].
Mechanism of preventive pacing
The number of AF episodes in SSS patients may be re-
duced by pacing in the atria. Preventive pacing inhibits
AF by averting sinus bradycardia or by suppressingpremature beats. AF initiation by premature beats was
studied by Duytschaever et al. [24]. In the goat model of
AF, the investigators revealed that preventive pacing re-
duced the window of inducibility by preventing the oc-
currence of late premature beats. Preventive pacing was
more effective when close to areas of conduction block
and remote from the origin of premature beats. How-
ever, preventive pacing may be difficult as there may be
multiple areas of conduction block in patients with dis-
eased atria. In addition, single or multiple premature
beats can originate from different sites within the right
or left atrium [24].
Inhibition of AF induction by pacing from the high
right atrium (HRA) and dCS was examined during elec-
trophysiological studies in 13 patients by Papageorgiou
et al. [25]. Atrial extra stimuli were applied from the
HRA during pacing from both the HRA and dCS.
Stimulation from the HRA was often unable to suppress
AF induction, but dCS pacing suppressed AF induction
at the same coupling intervals. dCS pacing significantly
prolonged the coupling interval of atrial extrastimuli at
the posterior triangle of Koch. The investigators pro-
posed that dCS pacing limits the induction of AF by
diminishing prematurity of atrial extrastimuli in the area
of the posterior angle of Koch. This, in turn, might pre-
vent local conduction delay and reentry [25]. In a study
by Verlato et al. pacing from the interatrial septum
(right above the CS ostium) only prevented development
of persistent AF in patients with atrial conduction delay
at the triangle of Koch [17]. Possibly, these patients are
more susceptible to atrial ectopy originating in this area.
However, pacing at the dCS may also prevent AF induc-
tion due to ectopic beats arising from other areas.
Preferential pacing modalities and sites
The first results of pacing in the coronary sinus (CS), were
published by Moss and Rivers in 1978 [26]. He reported
on a 10-year experience of CS pacing in a total number of
50 patients. Five years after implantation, more than 75%
of the patients had appropriate CS pacing. Recurrences of
difficult-to-treat supraventricular and ventricular tachyar-
rhythmias were prevented by CS pacing in four patients.
Despite the limited experience with cardiac pacing in the
late sixties and early seventies, the investigators assumed
that pacing would become a treatment modality for recur-
rent atrial tachyarrhythmias [26]. However, CS leads were
difficult to implant and occasionally resulted in perfor-
ation of the CS. RAA pacing was therefore developed as
an alternative site for CS pacing [27]. RAA pacing in SSS
patients was associated with a high level of intra-atrial
conduction disturbances as reflected by prolonged P-wave
width and a high incidence of AF recurrences [28].
Saksena et al. combined RAA pacing with proximal CS
pacing and named this dual-site (DS) pacing [29]. In this
Ramdjan et al. Trials 2014, 15:445 Page 7 of 9
http://www.trialsjournal.com/content/15/1/445trial, 15 patients with drug-refractory AF and coexistence
of bradyarrhythmia were enrolled. The DS configuration
was used in the first three months after implantation. In
the last three months, patients were switched to single-site
RAA pacing. No AF recurrences were observed during DS
pacing, compared to five recurrences in 12 patients with
RAA stimulation (P =0.03). Hence, the results of DS
pacing were promising and it appeared to be feasible, safe,
effective and suitable for long-term application [29].
Next, the DAPPAF trial was designed to compare DS
pacing with proximal coronary sinus (pCS) pacing. One
recommendation made by these investigators in their pub-
lished study protocol was to perform a future study in
which pCS pacing would be compared with RAA pacing.
The aim of future studies should be to determine if the ex-
pected positive effect is caused by DS pacing or proximal
CS pacing alone. At that time, pCS pacing could not be
compared with RAA pacing due to technical limitations.
The RAA lead was connected to the negative connector of
the bipolar adapter and the CS lead to the positive con-
nector. A dual bipolar set-up could not be established with
the use of the approved bipolar adapter. DS pacing could
be switched to single-site RAA pacing by selecting uni-
polar pacing only. Therefore, the investigators were unable
to program solely pCS pacing [30]. Enrolled patients in
the Riverleft trial will receive a conventional dual-chamber
pacemaker with one atrial and ventricular channel. No
bipolar adapter is required to bifurcate the atrial stimu-
lus. Therefore, technical requirements for the selected
pacemaker and lead configuration are less extensive,
compared to the studies conducted by Saksena et al.
and Fitts et al. [29,30].
Different pacing algorithms for prevention of atrial
tachyarrhythmias were tested by Blanc et al. with little
success; only a subgroup of patients with a low percent-
age of ventricular pacing benefitted from atrial pacing
[31]. However, the atrial lead was implanted at the con-
ventional site (RAA).
A substudy by Mirza et al. examined lead performance
over time and safety in the pCS position [32]. No lead
dislodgements or adverse events were reported and the
group concluded that permanent CS pacing is safe and
feasible, even though active lead fixation was not used in
this study. It has been demonstrated that active fixation
in the CS shows good stability and safety compared to
passive fixation [33,34]. Based on the assumption by
Papageorgiou et al. [25] that dCS pacing diminishes pre-
maturity of the atrial extra stimuli in the posterior tri-
angle of Koch, Breuls et al. initiated a pilot study to
compare dCS pacing with RAA pacing [35]. They dem-
onstrated that left atrial stimulation tends to be more ef-
fective than right atrial stimulation in terms of reduction
of AF episodes and improvement in quality of life in SSS
patients with paroxysmal AF.Evaluation of atrial fibrillation episodes
Ricci et al. evaluated the capability of HM to detect AF ep-
isodes in 166 patients [15]. The investigators concluded
that HM allows early AF detection which, in turn, can re-
sult in an earlier intervention by a clinician [15]. Feasibility
and safety of HM was already acknowledged by ‘The
Lumos-T Safely RedUceS RouTine Office Device Follow-
up’ (TRUST) trial which included 1339 patients with an
implantable cardioverter defibrillator. Participants were
randomized in a 2:1 ratio to HM only or conventional out-
patient clinic visits after 3, 6, 9, 12 and 15 months follow-
up. Three and 15-month HM evaluations were performed
in conjunction with a clinical visit of the patient. Sched-
uled and unscheduled clinic visits, morbidity and elapsed
time between recorded event and clinical evaluation were
assessed. Up to a 45% decrease of clinical pacemaker as-
sessments was achieved with HM only evaluations, with-
out affecting morbidity. Less than 15% of all HM only
evaluations required unscheduled clinic visits. The TRUST
investigators concluded that remote monitoring can be
regarded as a safe alternative to conventional follow-up
and allows a more rapid response after a recorded event
[16]. However, the Heart Rhythm Society/ European Heart
Rhythm Association expert consensus recommended that
monitoring of cardiovascular implantable electronic de-
vices should be accompanied by an outpatient clinic visit
at least once a year [36]. No interval longer than six
months is scheduled in the three-year follow-up period of
the Riverleft trial. Use of remote monitoring was endorsed
in the most recent guidelines on cardiac pacing and
resynchronization therapy of the European Society of
Cardiology [37].
Study design
The Dutch Dual-site Right Atrial Pacing for Prevention of
Atrial Fibrillation (DRAPPAF) trial randomized 26 pa-
tients with symptomatic drug-refractory AF between DS
pacing and RAA pacing, but patients with underlying
sinus node disease were not included [38]. At hospital dis-
charge, patients were randomized to DS pacing or RAA
pacing for a duration of six months. After this period, par-
ticipants were crossed over to the other group. No pa-
tients in the DS pacing group required cardioversions or
deteriorated to permanent AF, compared to four and one
participants, respectively in the RAA pacing group [38]. In
the earlier mentioned trial of Saksena et al., 15 patients
with SSS and episodes of AF were crossed-over from DS
pacing after 90 days to RAA pacing for a period of three
months [29]. Consequently no run-in time was acknowl-
edged and the efficacy of a pacing modality could have
been over- or underestimated due to a carry-over effect.
The Riverleft study differs from the DRAPPAF study and
the study by Saksena et al. in the absence of a crossover
design. Follow-up periods of six (DRAPPAF study) and 12
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short to assess the preventive effect of CS pacing and to
compare this with conventional RAA pacing.
Registration of AF episodes in both studies could only
be established by complaints of the participant or by
patient-activated ECG recording. Due to integration of
HM in the Riverleft study, symptomatic and asymptom-
atic AF episodes will be registered automatically. There-
fore, the Riverleft investigators will be able to reveal a
more reliable quantification of the AF burden in the two
study groups.
Limitations
Accurate AF detection depends on proper sensing and
pacemaker programming. FFRW sensing could be a con-
siderable problem if CS pacing is intended. Therefore,
careful inspection of adequate atrial sensing (levels) and
FFRW signals should be carried out during the implant-
ation procedure and be confirmed at each follow-up
visit. The patient will be excluded from further participa-
tion if there is a marginal low atrial sensing or persistent
high amplitudes of FFRW signals.
HM will only send a triggered message after at least 20
mode switches a day. This restriction will limit the abil-
ity to detect the first onset of AF recurrence after pace-
maker implantation. Besides mode switch registration,
high atrial rate will be used to register AF episodes. In
contrast to mode switches, one episode of high atrial
rate will trigger a HM message. The disparity between
both study arms for location of implanted ventricular
lead, should be monitored carefully. A high number of
implanted leads in the RVOT, could influence the out-
come for the respective study arm.
Trial status
Inclusion of eligible candidates in the Riverleft study has
not yet started and is expected to start in November 2014.
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